Eli Lilly and Company (LLY) on Thursday reported positive results from its Phase 3 ACHIEVE-3 trial evaluating orforglipron in adults with type 2 diabetes inadequately controlled on metformin, compared with oral semaglutide.
In the 52-week study, orforglipron outperformed semaglutide across the primary and all key secondary endpoints, showing significantly greater reductions in A1C and body weight. Specifically, orforglipron lowered A1C by 2.2%, compared with a 1.4% reduction for semaglutide.
The results were published today in The Lancet.
Lilly has submitted orforglipron to regulators in over 40 countries and plans to submit for U.S. approval for type 2 diabetes later this year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.